Steven A. Everett, MBA, Ph.D.
Founder and Chief Executive Officer
Prof. Everett is a Co-Founder of Cyterix Pharmaceuticals and has served as joint CEO and CSO since the company was incorporated in April 2010. He is the inventor of the proprietary Cyterix OncoCYP™ prodrug discovery approach. Prof. Everett has 19 years experience in the discovery and pre-clinical development of prodrugs for targeted cancer therapy both in academia and the biotech industry. He retains his academic position at the University of California, San Francisco as an Adjunct Faculty member and was previously the Head of the Drug Discovery and Translational Research Group at the University of Dundee in Scotland from 2005 to 2009. He was a Principal Investigator on a Cancer Research UK-funded program of research to develop innovative prodrug strategies for the treatment of cancer. From 2008 to 2010 Prof. Everett was a consultant and a member of the scientific advisory board of Threshold Pharmaceuticals a public company with hypoxia-activated prodrugs in advanced clincial development. From 2003 to 2005 Prof. Everett served on the board of directors of Spear Therapeutics and continued to consult for the company until 2009 in prodrug discovery and translational biology. In 1992 he was recruited to the Gray Laboratory now the Gray Institute for Radiation Oncology and Biology affiliated to the University of Oxford. Over 13 years he advanced to Senior Scientist and specialized in rational ‘mechanism-led’ prodrug design focussing on the discovery and development of hypoxia-activated prodrugs for cancer treatment. Prof. Everett is a co-author of over 50 peer-reviewed scientific papers and is an inventor on 10 issued or pending patents. Prof. Everett holds a B.Sc. in chemistry and biology from the University of Ulster, a Ph.D in physical chemistry from the Hahn-Meitner Institut Berlin and an MBA with distinction from Brunel University near London.
Chief Financial Officer
Mr. Bayol brings over 30 years of finance, accounting and operations experience to his consulting role as interim Chief Financial Officer at Cyterix Pharmaceuticals. Previously, he held consulting roles at NGM Biopharmaceuticals and Igenica as interim CFO. Prior to his consulting roles, he was Director of Operations at Amgen, Treasurer at Tularik and held various finance and accounting positions at Lynx Therapeutics, NeXT Computer and Applied Biosystems. A graduate of San Jose State University with a B.S. in Business Administration, Mr. Bayol is a Certified Public Accountant (inactive) in the State of California.
Human Resource Officer
Mr. Smith has spent the last 30 years in human resources in the high technology and biotechnology industries. He spent several years with Intel in during the early stages of the company, and was with ESL, a systems integration company where he held a number of roles, finally supporting technology diversification and the spin-out of companies based on that diversification. Chris moved to the biotechnology industry in 1996, at Tularik Inc., where he was the Vice President of Human Resources. Chris brings a blend of practical business experience, an understanding of organizations, along with human resources skills to support the creation of successful companies. Prior to his Silicon Valley experience, Chris spent several years in the UK and was educated in Perth, Australia.